Submitted for Publication: July 27, 2010; final revision received January 11, 2011; accepted February 22, 2011.
Published Online: May 2, 2011. doi:10.1001/archgenpsychiatry.2011.51
Author Contributions: Drs Brody and Mandelkern had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Financial Disclosure: Drs London and Mukhin received support from Philip Morris USA for research other than the project presented here.
Funding/Support: This study was supported by grant 16RT-0098 from the Tobacco-Related Disease Research Program (Dr Brody), grant R01 DA20872 from the National Institute on Drug Abuse (Dr Brody), a Veterans Affairs Type I Merit Review Award (Dr Brody), grant DABT63-00-C-1003 from the Office of National Drug Control Policy (Dr London), and endowments from the Richard Metzner Chair in Clinical Neuropharmacology (Dr Brody), the Thomas P. and Katherine K. Pike Chair in Addiction Studies (Dr London), and the Marjorie Greene Family Trust (Dr London).
Role of the Sponsors: The funders of this study had no role in the design or conduct of the study; in the collection, management, analysis, or interpretation of the data; or in the preparation, review, or approval of the manuscript.
Additional Contributions: Catherine Sugar, PhD, provided statistical consultation for the study. Josephine Ribe, BS, and Michael Clark, BS, provided technical support in performing PET and magnetic resonance imaging scans, respectively.